Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
复制标题
DOI：
10.5588/ijtld.11.0068
复制
发表时间：
2011-11
期刊：
影响因子：
--
通讯作者：
Narita M
中科院分区：
文献类型：
--
作者：
Horne DJ;Spitters C;Narita M
在抗结核治疗方案中使用利福霉素对于缩短治疗、获得良好的治愈率和复发率至关重要；利福平是推荐的利福霉素。与利福平相关的不良反应(AE)可能需要停用。虽然利福平是一种具有抗结核活性的利福霉素，其声发射谱与利福平不同，但其在利福平相关性脑脊髓炎患者中的应用尚未得到很好的研究。我们回顾了利福布汀治疗结核病的经验。我们回顾了2003-2009年在治疗方案中接受利福平治疗的肺结核病例。我们评估了利福布汀的使用适应症；对于经历了药物相关性AE的患者，我们对AE与利福平相关的可能性进行了分类。通过Logistic回归分析，我们发现利福平相关的不良反应与利福平不耐受有关。100名受试者符合纳入标准。利福布汀的使用适应症是57名患者(57%)与利福平相关的AE，同时进行抗逆转录病毒治疗(21%)，与其他药物潜在/实际相互作用(14%)，以及作为肝病替代方案的一部分(8%)。在既往有利福平相关性AE的患者中，80%的患者成功地使用利福布汀治疗。19名患者在服用利福布汀时发生了AE。在既往有利福平相关的AE的患者中，只有皮肤科的AE与随后的利福平不耐受有关。我们的研究表明，利福平对发生利福平相关性急性脑炎的患者耐受性良好。经历过利福平相关皮肤病事件的患者可能会增加患利福平相关AE的风险。
The use of a rifamycin in anti-tuberculosis treatment regimens is crucial for shortening treatment and achieving favorable cure and relapse rates; rifampin is the recommended rifamycin. Adverse effects (AE) related to rifampin may require its discontinuation. Although rifabutin is a rifamycin with activity against M. tuberculosis and a different AE profile than rifampin, its use in patients with a rifampin-related AE is not well studied. We reviewed our experience with rifabutin in the treatment of tuberculosis. We reviewed tuberculosis cases (2003–2009) who received rifabutin in their treatment regimen. We evaluated the indications for rifabutin use; for patients that experienced a drug-related AE, we categorized the likelihood that the AE was rifampin-related. Using logistic regression analysis, we identified rifampin-related AEs associated with rifabutin intolerance. One hundred subjects met inclusion criteria. The indications for rifabutin use were a rifampin-related AE in 57 patients (57%), concurrent anti-retroviral therapy (21%), a potential/actual interaction with other medications (14%), and as part of an alternative regimen due to liver disease (8%). Of patients with a prior rifampin-related AE, 80% were successfully treated with rifabutin. Nineteen patients experienced an AE while taking rifabutin. Among patients with a previous rifampin-related AE, only a dermatologic AE was associated with subsequent rifabutin intolerance. Our study suggests that rifabutin is well tolerated by patients who develop rifampin-related AEs. Patients who experienced a rifampin-related dermatologic event may be at increased risk for a rifabutin-related AE.
登录
查看更多内容
影响因子：
6.4
作者：
Onyebujoh, Philip Chukwuka;Ribeiro, Isabela;Whalen, Christopher Curtis
通讯作者：
Whalen, Christopher Curtis
影响因子：
11.8
作者：
Li, JH;Munsiff, SS;Sackoff, J
通讯作者：
Sackoff, J
DOI：
10.1164/rccm.200503-417oc
发表时间：
2006-02-01
影响因子：
24.7
作者：
Burman, W;Benator, D;El-Sadr, W
通讯作者：
El-Sadr, W
影响因子：
1.6
作者：
Martínez, E;Collazos, J;Mayo, J
通讯作者：
Mayo, J
DOI：
10.1016/s0962-8479(05)80007-3
发表时间：
1995-06-01
期刊：
TUBERCLE AND LUNG DISEASE
影响因子：
--
作者：
SCHWANDER, S;RUSCHGERDES, S;DIETRICH, M
通讯作者：
DIETRICH, M